Target Name: LMAN2L
NCBI ID: G81562
Review Report on LMAN2L Target / Biomarker Content of Review Report on LMAN2L Target / Biomarker
LMAN2L
Other Name(s): Lectin mannose-binding 2-like | MRD69 | LMAN2-like protein | lectin, mannose binding 2 like | VIP36-like protein | LMAN2L variant 1 | LMA2L_HUMAN | Lectin, mannose binding 2 like, transcript variant 1 | VIP36-like protein (isoform 1) | VIPL | MRT52

LMAN2L as A Potential Drug Target for Diabetes

LMAN2L (Lectin mannose-binding 2-like) is a protein that is expressed in various tissues of the human body, including the brain, pancreas, and gastrointestinal tract. It is a type of transmembrane protein that is characterized by the presence of a N -terminal extracellular domain, a transmembrane region, and an C-terminal cytoplasmic domain. LMAN2L is involved in various physiological processes in the body, including cell signaling, neurotransmission, and insulin sensitivity.

Disease and Treatment

LMAN2L is involved in various diseases and disorders, including diabetes, neurodegenerative diseases, and cancer. It is also a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In the context of diabetes, LMAN2L is a potential drug target because it is involved in insulin sensitivity and glucose metabolism. Diabetes is a serious disease that affects millions of people worldwide, and there is a need for new treatments that can improve insulin sensitivity and reduce the risk of complications. LMAN2L is a protein that is involved in insulin sensitivity, and therefore it could be a useful target for new diabetes treatments.

In neurodegenerative diseases, LMAN2L is involved in the development and progression of these diseases. neurodegenerative diseases are a group of disorders that are characterized by the progressive loss of neural cells and their corresponding neural circuits. These disorders include Alzheimer's disease, Parkinson's disease, and Huntington's disease. LMAN2L is involved in the development and progression of these diseases, and therefore it could be a useful target for new neurodegenerative disease treatments.

In cancer, LMAN2L is involved in the development and progression of cancer. Cancer is a serious disease that affects millions of people worldwide, and there is a need for new treatments that can improve treatment outcomes. , and therefore it could be a useful target for new cancer treatments.

Current Treatments

Currently, there are several treatments available for diabetes, neurodegenerative diseases, and cancer. However, these treatments have several limitations. For example, many of these treatments can cause side effects, and there is a need for new treatments that can provide better outcomes without these side effects.

In the context of diabetes, current treatments include lifestyle modifications, diet changes, and medications such as metformin, piagetin, and GLP-1 receptor agonists. These treatments can improve insulin sensitivity and reduce the risk of complications, but they can also cause side effects such as diarrhea, nausea, and vomiting.

In neurodegenerative diseases, current treatments include medications such as dopamine agonists, antipsychotic medications, and neuroprotective agents. These treatments can improve quality of life and reduce the risk of complications, but they can also cause side effects such as movement disorders, dizziness, and changes in mood.

In cancer, current treatments include chemotherapy, radiation therapy, and targeted therapies. These treatments can improve treatment outcomes and reduce the risk of recurrence, but they can also cause side effects such as nausea, vomiting, and fatigue.

The Potential Role of LMAN2L

The potential role of LMAN2L as a drug target is based on its involvement in insulin sensitivity, neurodegenerative diseases, and cancer. LMAN2L is a protein that is involved in several physiological processes, including cell signaling, neurotransmission, and insulin sensitivity.

In the context of diabetes, LMAN2L is involved in insulin sensitivity and glucose metabolism. Diabetes is a serious disease that affects millions of people worldwide, and there is a need for new treatments that can improve insulin sensitivity and reduce the risk of complications. LMAN2L is a protein that is involved in insulin sensitivity,

Protein Name: Lectin, Mannose Binding 2 Like

Functions: May be involved in the regulation of export from the endoplasmic reticulum of a subset of glycoproteins. May function as a regulator of ERGIC-53

The "LMAN2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMAN2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107